TD Cowen raises Vertex stock price target on strong growth prospects
Covered in this story
What has happened since
- Vertex Pharmaceuticals is up 1.5% since this was published, 11 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
TD Cowen’s $575 target on $VRTX is on the record and being tracked to Nov 2027 (12-month default), scored on the close that day.
TD Cowen’s track record →Analyst targets on Vertex Pharmaceuticals
- Stifel: at $531 · target $563 by Nov 2027 · Hold via Investing.com
- UBS: at $528 · target $615 by Sep 2027 · Buy via Investing.com
- H.C. Wainwright: at $515 · target $641 by Sep 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $VRTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Vertex Pharmaceuticals →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.